α1‑adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta‑analysis

Zhang,Peng; Hu,Wan‑Li; Cheng,Bei; Cheng,Long; Xiong,Xiao‑Kan

doi:10.3892/etm.2015.2445

α1‑adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta‑analysis

Authors:
- Peng Zhang
- Wan‑Li Hu
- Bei Cheng
- Long Cheng
- Xiao‑Kan Xiong
View Affiliations

Affiliations: Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Anatomy and Embryology, School of Medicine, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Endocrinology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China
Published online on: April 23, 2015 https://doi.org/10.3892/etm.2015.2445
Pages: 251-256

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the effectiveness of α1‑adrenergic receptor antagonists (α1ARAs) versus placebo for female patients with lower urinary tract symptoms (LUTS). A meta‑analysis of randomized controlled trials was conducted. The main outcome indices used to measure the effectiveness were the total International Prostate Symptom Score (I‑PSS) and maximum urinary flow rate of female patients receiving treatment for LUTS. The I‑PSS quality of life (QOL) and average urinary flow rate (AFR) were also observed and analyzed. Two randomized controlled trials with a total of 213 patients were included. Meta‑analysis results were as follows: Following 4 weeks of treatment, patients taking α1ARAs presented a significant advantage over patients under placebo in terms of total I‑PSS [standardized mean difference (SMD), ‑0.67; 95% confidence interval (CI), ‑0.94 to ‑0.39] but no difference was observed in maximum urinary flow rate (SMD, ‑0.05; 95% CI, ‑0.32 to 0.22) between the experimental and control groups. The I‑PSS QOL post‑treatment was lower in the α1ARA group compared with that in the placebo group (SMD, ‑0.86; 95% CI, ‑1.32 to ‑0.40) according to one study, and in the other study the improvement of AFR was not significant (SMD, 0.09; 95% CI, ‑0.25 to 0.43). It was concluded that α1ARAs are more effective than placebo in female patients with LUTS.

View Figures

View References

1	Fitzpatrick JM: Facts and future lines of research in lower urinary tract symptoms in men and women: An overview of the role of α1-adrenoreceptor antagonist. BJU Int. 85:(Suppl 2). 1–5. 2000. View Article : Google Scholar : PubMed/NCBI
2	Møller LA, Lose G and Jørgensen T: The prevalence and bothersomeness of lower urinary tract symptoms in women 40–60 years of age. Acta Obstet Gynecol Scand. 79:298–305. 2000. View Article : Google Scholar : PubMed/NCBI
3	Wennberg AL, Molander U, Fall M, Edlund C, Peeker R and Milsom I: A longitudinal population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in women. Eur Urol. 55:783–791. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wehrberger C, Madersbacher S, Jungwirth S, Fischer P and Tragl KH: Lower urinary tract symptoms and urinary incontinence in a geriatric cohort - a population-based analysis. BJU Int. 110:1516–1521. 2012. View Article : Google Scholar : PubMed/NCBI
5	Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, Chapple CR, Kaplan S, Tubaro A, Aiyer LP and Wein AJ: The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: Results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 104:352–360. 2009. View Article : Google Scholar : PubMed/NCBI
6	Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, Chen CI and Quentin Clemens J: The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourol Urodyn. 32:230–237. 2013. View Article : Google Scholar : PubMed/NCBI
7	Choi YS, Kim JC, Lee KS, Seo JT, Kim HJ, Yoo TK, Lee JB, Choo MS, Lee JG and Lee JY: Analysis of female voiding dysfunction: A prospective, multi-center study. Int Urol Nephrol. 45:989–994. 2013. View Article : Google Scholar : PubMed/NCBI
8	Schwinn DA and Roehrborn CG: Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 15:193–199. 2008. View Article : Google Scholar : PubMed/NCBI
9	Malloy BJ, Price DT, Price RR, Bienstock AM, Dole MK, Funk BL, Rudner XL, Richardson CD, Donatucci CF and Schwinn DA: Alpha1-adrenergic receptor subtypes in human detrusor. J Urol. 160:937–943. 1998. View Article : Google Scholar : PubMed/NCBI
10	Andersson KE: Mode of action of alpha1-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms. BJU Int. 85:(Suppl 2). 12–18. 2000. View Article : Google Scholar : PubMed/NCBI
11	Michel MC and Vrydag W: Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 147:(Suppl 2). S88–S119. 2006. View Article : Google Scholar : PubMed/NCBI
12	Nasu K, Moriyama N, Fukasawa R, Tsujimoto G, Tanaka T, Yano J and Kawabe K: Quantification and distribution of α1-adrenoreceptor subtype mRNAs in human proximal urethra. Br J Pharmacol. 123:1289–1293. 1998. View Article : Google Scholar : PubMed/NCBI
13	Serels S and Stein M: Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodyn. 17:31–36. 1998. View Article : Google Scholar : PubMed/NCBI
14	Chang SJ, Chiang IN and Yu HJ: The effectiveness of tamsulosin in treating women with voiding difficulty. Int J Urol. 15:981–985. 2008. View Article : Google Scholar : PubMed/NCBI
15	Low BY, Liong ML, Yuen KH, Chee C, Leong WS, Chong WL, Khan NA, Cheah PY and Liong KK: Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. J Urol. 179:1461–1469. 2008. View Article : Google Scholar : PubMed/NCBI
16	Pummangura N and Kochakarn W: Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian J Surg. 30:131–137. 2007. View Article : Google Scholar : PubMed/NCBI
17	Lepor H and Theune C: Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. J Urol. 154:116–118. 1995. View Article : Google Scholar : PubMed/NCBI
18	Kakizaki H and Koyanagi T: Current view and status of the treatment of lower urinary tract symptoms and neurogenic lower urinary tract dysfunction. BJU Int. 85:(Suppl 2). 25–30. 2000. View Article : Google Scholar : PubMed/NCBI